<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26960936</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>01</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1991</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>59</Volume>
            <Issue>2-3</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell calcium</Title>
          <ISOAbbreviation>Cell Calcium</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Calcium signalling in pancreatic stellate cells: Mechanisms and potential roles.</ArticleTitle>
        <Pagination>
          <StartPage>140</StartPage>
          <EndPage>144</EndPage>
          <MedlinePgn>140-4</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ceca.2016.02.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0143-4160(16)30008-2</ELocationID>
        <Abstract>
          <AbstractText>Hepatic and pancreatic stellate cells may or may not be regarded as stem cells, but they are capable of remarkable transformations. There is less information about stellate cells in the pancreas than in the liver, where they were discovered much earlier and therefore have been studied longer and more intensively than in the pancreas. Most of the work on pancreatic stellate cells has been carried out in studies on cell cultures, but in this review we focus attention on Ca(2+) signalling in stellate cells in their real pancreatic environment. We review current knowledge on patho-physiologically relevant Ca(2+) signalling events and their underlying mechanisms. We focus on the effects of bradykinin in the initial stages of acute pancreatitis, an often fatal disease in which the pancreas digests itself and its surroundings. Ca(2+) signals, elicited in the stellate cells by the action of bradykinin, may have a negative effect on the outcome of the acute disease process and promote the development of chronic pancreatitis. The bradykinin-elicited Ca(2+) signals can be inhibited by blockade of type 2 receptors and also by blockade of Ca(2+)-release activated Ca(2+) channels. The potential benefits of such pharmacological inhibition for the treatment of pancreatitis are reviewed.</AbstractText>
          <CopyrightInformation>Copyright Â© 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gryshchenko</LastName>
            <ForeName>Oleksiy</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK; Bogomoletz Institute of Physiology, Kiev 01024, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gerasimenko</LastName>
            <ForeName>Julia V</ForeName>
            <Initials>JV</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gerasimenko</LastName>
            <ForeName>Oleg V</ForeName>
            <Initials>OV</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petersen</LastName>
            <ForeName>Ole H</ForeName>
            <Initials>OH</Initials>
            <AffiliationInfo>
              <Affiliation>Medical Research Council Group, Cardiff School of Biosciences, Cardiff University, Cardiff CF10 3AX, Wales, UK. Electronic address: PetersenOH@cardiff.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>G19/22</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MR/J002771/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>02</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Cell Calcium</MedlineTA>
        <NlmUniqueID>8006226</NlmUniqueID>
        <ISSNLinking>0143-4160</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044139">Receptor, Angiotensin, Type 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S8TIM42R2W</RegistryNumber>
          <NameOfSubstance UI="D001920">Bradykinin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001920" MajorTopicYN="N">Bradykinin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058954" MajorTopicYN="N">Pancreatic Stellate Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044139" MajorTopicYN="N">Receptor, Angiotensin, Type 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bradykinin</Keyword>
        <Keyword MajorTopicYN="N">Bradykinin receptors</Keyword>
        <Keyword MajorTopicYN="N">Calcium entry</Keyword>
        <Keyword MajorTopicYN="N">Calcium release</Keyword>
        <Keyword MajorTopicYN="N">Calcium signalling</Keyword>
        <Keyword MajorTopicYN="N">Kallikrein</Keyword>
        <Keyword MajorTopicYN="N">Kininogen</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26960936</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ceca.2016.02.003</ArticleId>
        <ArticleId IdType="pii">S0143-4160(16)30008-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
